Company Filing History:
Years Active: 2025
Title: Michael Lyman: Innovator in Cancer Treatment
Introduction
Michael Lyman is a prominent inventor based in La Jolla, California. He is known for his significant contributions to the field of cancer treatment through innovative research and development. His work focuses on the use of oncolytic adenoviruses, which are engineered to selectively target and destroy tumor cells.
Latest Patents
Lyman holds a patent for an "Oncolytic adenovirus with enhanced replication properties comprising modifications in E1A, E3, and E4." This patent describes tumor-selective recombinant adenoviruses that possess deletions or modifications in the E3 region. The recombinant adenoviruses express adenovirus death protein (ADP) while having a deletion of at least three of the remaining six E3 genes, which enhances virus replication. Furthermore, these adenoviruses include additional modifications that allow for selective replication in tumor cells and detargeting from the liver. The use of these recombinant adenoviruses for cancer treatment is a significant advancement in the field.
Career Highlights
Michael Lyman is affiliated with the Salk Institute for Biological Studies, where he conducts groundbreaking research. His work has the potential to revolutionize cancer therapies and improve patient outcomes. Lyman's innovative approach to utilizing adenoviruses in cancer treatment showcases his commitment to advancing medical science.
Collaborations
Lyman collaborates with esteemed colleagues, including Clodagh O'Shea and William N Partlo. Their combined expertise contributes to the success of their research initiatives and enhances the potential impact of their findings.
Conclusion
Michael Lyman is a key figure in the development of innovative cancer treatments through his work with oncolytic adenoviruses. His patent and research efforts at the Salk Institute for Biological Studies highlight his dedication to improving cancer therapies. The advancements made by Lyman and his collaborators hold promise for the future of cancer treatment.